Alzheimers disease dementia
Conditions
Interventions
Blood-based biomakers for Alzheimers disease.
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Patient presents in memory clinic with cognitive complaints or behavioral change. - The physician is concerned about underlying AD as etiology of the complaints. - Adequate fluency in Dutch to understand informed consent procedure.
Exclusion criteria
Exclusion criteria: - Age under 55. - Previous biomarker-confirmed diagnosis of AD. - Alcohol or drug abuse to such an extent that treatment would be advisable. - Patient is incapacitated, and is not able to judge consequences of participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences between the intervention group (those who receive BBM test results) and the control group (those who do not receive a BBM test result) in: - Time from baseline to final diagnosis. Comparison before and after BBM testing within the intervention group: - Change in working diagnosis. - Change in physician's confidence in diagnosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints Differences between the intervention group and the control group in patient management and use and timing of resources, specifically: - Other ancillary tests, such as brain CT/MRI, CSF biomarker analysis, amyloid PET scan. - Follow-up yes / no, and duration of follow-up if *yes*. - Referral to other specialist / center. Concordance of BBM results with AD pathology according to CSF or amyloid PET. Other endpoints - Usefulness of AD BBMs per case, as perceived by the physician. - Qualitative evaluation of patient perspectives on receiving BBM results. - Cognitive performance measured by cognitive tests according to local standard clinical work-up. - Prior medical history, drug and medication use: information regarding prior medical history and drug / medication use will be collected. We will investigate whether these factors can influence concentrations of the BBMs. - Cognition, quality of life, iADL functioning and healthcare utilisation over time as well as mortality. This follow-up is optional. | — |
Countries
Netherlands
Contacts
Public ContactPI Vanneste
Amsterdam UMC
Outcome results
None listed